Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.

Further clinical trials, including registry-based analyses, are urgently needed to better define the patient characteristics, efficacy and safety profile of AHSCT compared with other high-efficacy therapies and to optimally position it as a treatment option in different MS disease stages.